DK2215047T3 - Fremgangsmåde til behandling af vitamin b12-mangel - Google Patents

Fremgangsmåde til behandling af vitamin b12-mangel

Info

Publication number
DK2215047T3
DK2215047T3 DK08844673.7T DK08844673T DK2215047T3 DK 2215047 T3 DK2215047 T3 DK 2215047T3 DK 08844673 T DK08844673 T DK 08844673T DK 2215047 T3 DK2215047 T3 DK 2215047T3
Authority
DK
Denmark
Prior art keywords
lack
treating vitamin
vitamin
treating
Prior art date
Application number
DK08844673.7T
Other languages
Danish (da)
English (en)
Inventor
Laura Kragie
Cristina Castelli
Original Assignee
Emisphere Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40591491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2215047(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Emisphere Tech Inc filed Critical Emisphere Tech Inc
Application granted granted Critical
Publication of DK2215047T3 publication Critical patent/DK2215047T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135Compounds containing heavy metals
    • A61K31/714Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK08844673.7T 2007-11-02 2008-10-31 Fremgangsmåde til behandling af vitamin b12-mangel DK2215047T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US98489807P 2007-11-02 2007-11-02
US2010808P 2008-01-09 2008-01-09
US8356608P 2008-07-25 2008-07-25
PCT/US2008/082064 WO2009059188A1 (en) 2007-11-02 2008-10-31 Method of treating vitamin b12 deficiency

Publications (1)

Publication Number Publication Date
DK2215047T3 true DK2215047T3 (da) 2014-02-03

Family

ID=40591491

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08844673.7T DK2215047T3 (da) 2007-11-02 2008-10-31 Fremgangsmåde til behandling af vitamin b12-mangel

Country Status (18)

Country Link
US (3) US8022048B2 (enExample)
EP (1) EP2215047B1 (enExample)
JP (1) JP5555634B2 (enExample)
KR (1) KR101344369B1 (enExample)
CN (1) CN101952241B (enExample)
AU (1) AU2008318423B2 (enExample)
BR (1) BRPI0817396C8 (enExample)
CA (1) CA2704780C (enExample)
CL (1) CL2010000434A1 (enExample)
CO (1) CO6280475A2 (enExample)
DK (1) DK2215047T3 (enExample)
ES (1) ES2443817T3 (enExample)
MX (1) MX2010004716A (enExample)
NZ (1) NZ585080A (enExample)
PL (1) PL2215047T3 (enExample)
PT (1) PT2215047E (enExample)
RU (1) RU2469728C2 (enExample)
WO (1) WO2009059188A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5985985B2 (ja) * 2009-08-03 2016-09-06 エミスフィアー テクノロジーズ インコーポレイテッドEmisphere Technologies,Inc. 胃腸への影響が減少した即効型ナプロキセン組成物
KR20130026429A (ko) * 2010-02-24 2013-03-13 에미스페어 테크놀로지스, 인코포레이티드 경구 b12 치료요법
RS56998B1 (sr) 2010-12-16 2018-05-31 Novo Nordisk As Čvrste kompozicije koje sadrže agonist glp-1 i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
EP2696687B1 (en) 2011-04-12 2016-10-26 Novo Nordisk A/S Double-acylated glp-1 derivatives
US8805208B2 (en) * 2012-02-03 2014-08-12 Tyco Electronics Subsea Communications Llc System and method for polarization de-multiplexing in a coherent optical receiver
CN104203266B (zh) 2012-03-22 2017-12-26 诺和诺德股份有限公司 Glp‑1肽组合物及其制备
ES2965469T3 (es) 2012-03-22 2024-04-15 Novo Nordisk As Composiciones que comprenden un agente de suministro y preparación de estas
DK2827845T3 (en) 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
CN104487056A (zh) 2012-06-20 2015-04-01 诺和诺德A/S(股份有限公司) 包含肽和递送剂的片剂制剂
US20140309270A1 (en) 2013-04-11 2014-10-16 Richard Louis Price Diagnosis and treatment of a form of autistic spectrum disorder
US9211284B2 (en) 2013-04-11 2015-12-15 Richard Louis Price Diagnosis and treatment of P.R.I.C.E. syndrome
US20170348417A1 (en) 2013-04-11 2017-12-07 Richard Louis Price Treatment of attention deficit disorders and associated symptoms
US9603812B2 (en) 2013-04-11 2017-03-28 Richard Louis Price Treatment of autistic spectrum disorder
US10098848B2 (en) 2013-04-11 2018-10-16 Richard Louis Price Inositol-containing comestible units and methods of treatment using the same
BR112015026325A2 (pt) 2013-05-02 2017-07-25 Novo Nordisk As dosagem oral de compostos glp-1
MX382853B (es) 2016-04-22 2025-03-13 Spoke Sciences Inc Compuestos medicinales y suplementos nutricionales de base vegetal de rápida acción.
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
US20200254041A1 (en) * 2017-10-05 2020-08-13 Receptor Holdings, Inc. Rapid onset and extended action plant-based and synthetic cannabinoid formulations
US20200268821A1 (en) * 2017-10-05 2020-08-27 Receptor Holdings, Inc. Herbal compositions with improved bioavailability
WO2019149880A1 (en) 2018-02-02 2019-08-08 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
AU2019385420A1 (en) 2018-11-19 2021-07-08 Spoke Sciences, Inc. N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665379A (en) * 1990-09-28 1997-09-09 Pharmacia & Upjohn Aktiebolag Lipid particle forming matrix, preparation and use thereof
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
CA2266412A1 (en) * 1996-09-18 1998-03-26 William J. Sarill Compositions containing cobalamin and amino acids
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
MXPA01006297A (es) * 1998-12-28 2002-06-04 Biogentec Inc Tratamiento con cianocobalamina (vitamina b12) para enfermedades alergicas.
IL145546A0 (en) 1999-04-05 2002-06-30 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
EP1535625B1 (en) 1999-04-05 2014-01-08 Novartis AG Composition containing n-(5-chlorosalicyloyl)-8-aminocaprylic acid and salmon calcitonin
JP4799794B2 (ja) * 2000-03-21 2011-10-26 エミスフェアー・テクノロジーズ・インク ジカルボキシル化中間体を介してアルキル化サリチルアミドを調製する方法。
US7049283B2 (en) 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
CA2446929C (en) 2001-06-01 2013-04-09 Novartis Ag Orally administering parathyroid hormone and calcitonin
JP4959917B2 (ja) 2001-08-17 2012-06-27 ノバルティス アーゲー 副甲状腺ホルモンフラグメント用経口送達剤としての5−cnac
US20050054557A1 (en) 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
TW200403052A (en) 2002-07-17 2004-03-01 Novartis Ag Use of organic compounds
AR040737A1 (es) 2002-08-01 2005-04-20 Novartis Ag Administracion oral de calcitonina
EP1545477A4 (en) 2002-09-13 2006-11-22 Cydex Inc CAPSULES CONTAINING AQUEOUS FILLING COMPOSITIONS STABILIZED WITH DERIVED CYCLODEXTRIN
CN100579955C (zh) 2003-04-04 2010-01-13 帝斯曼知识产权资产管理有限公司 N-烷氧基草酰丙氨酸酯的制备方法
US6938439B2 (en) 2003-05-22 2005-09-06 Cool Clean Technologies, Inc. System for use of land fills and recyclable materials
JP3924616B2 (ja) 2003-06-30 2007-06-06 独立行政法人物質・材料研究機構 微小サイズの温度感知素子を用いる温度計測方法
EP1643978A1 (en) 2003-07-04 2006-04-12 Nycomed Danmark A/S Parathyroid hormone (pth) containing pharmaceutical compositions for oral use
WO2005004900A1 (en) * 2003-07-11 2005-01-20 Novartis Ag Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
US7749954B2 (en) 2003-07-23 2010-07-06 Novartis Ag Use of calcitonin in osteoarthritis
JP4903690B2 (ja) * 2004-05-06 2012-03-28 エミスフェアー・テクノロジーズ・インク N−[8−(2−ヒドリキシベンゾイル)アミノ]カプリル酸一ナトリウムの結晶多形体
WO2006020291A2 (en) * 2004-08-02 2006-02-23 Bebaas, Inc. Vitamin b12 compositions
JP2008509933A (ja) 2004-08-13 2008-04-03 エミスフェアー・テクノロジーズ・インク 送達剤のマイクロ粒子またはナノ粒子を含む医薬製剤
US20060116334A1 (en) * 2004-12-01 2006-06-01 Curt Hendrix Folate based composition for treatment of the cardiovascular system
GB0427603D0 (en) 2004-12-16 2005-01-19 Novartis Ag Organic compounds
GB0427600D0 (en) 2004-12-16 2005-01-19 Novartis Ag Organic compounds
CA2626029A1 (en) * 2005-11-04 2007-05-18 Genta Incorporated Pharmaceutical gallium compositions and methods

Also Published As

Publication number Publication date
MX2010004716A (es) 2010-12-17
KR20100126263A (ko) 2010-12-01
AU2008318423B2 (en) 2013-12-05
CA2704780A1 (en) 2009-05-07
EP2215047A1 (en) 2010-08-11
BRPI0817396C1 (pt) 2020-11-17
US8288360B2 (en) 2012-10-16
JP5555634B2 (ja) 2014-07-23
HK1146480A1 (en) 2011-06-10
AU2008318423A1 (en) 2009-05-07
US8557792B2 (en) 2013-10-15
CN101952241B (zh) 2014-06-11
RU2469728C2 (ru) 2012-12-20
BRPI0817396C8 (pt) 2021-05-25
BRPI0817396B8 (pt) 2020-02-04
PT2215047E (pt) 2014-01-20
CO6280475A2 (es) 2011-05-20
US8022048B2 (en) 2011-09-20
CN101952241A (zh) 2011-01-19
CL2010000434A1 (es) 2011-01-28
BRPI0817396A2 (pt) 2015-04-07
JP2011502997A (ja) 2011-01-27
ES2443817T3 (es) 2014-02-20
NZ585080A (en) 2012-05-25
US20110293589A1 (en) 2011-12-01
KR101344369B1 (ko) 2013-12-24
EP2215047A4 (en) 2010-11-10
RU2010118423A (ru) 2011-12-10
WO2009059188A1 (en) 2009-05-07
EP2215047B1 (en) 2013-11-20
US20100016255A1 (en) 2010-01-21
BRPI0817396B1 (pt) 2019-04-24
US20130040910A1 (en) 2013-02-14
CA2704780C (en) 2014-06-10
PL2215047T3 (pl) 2014-05-30

Similar Documents

Publication Publication Date Title
DK2215047T3 (da) Fremgangsmåde til behandling af vitamin b12-mangel
DK2212070T3 (da) Fremgangsmåde til behandling af træ
DK2293816T3 (da) Fremgangsmåder til behandling af reumatoid arthritis
DK2148684T3 (da) Fremgangsmåde til behandling af vitamin D-insufficiens og -deficiens
BRPI0814359A2 (pt) Método
BRPI0817226A2 (pt) Método
BRPI0817726A2 (pt) Método
DK2325648T3 (da) Fremgangsmåde til detektering af cancer
DK2135664T3 (da) Fremgangsmåde til behandling af emissionsgas
BRPI0919116A2 (pt) método
DK1974806T3 (da) Fremgangsmåde til rensning af vand
DK3289876T3 (da) Forbindelser til behandling af cancer
DK2215031T3 (da) Fremgangsmåde til bearbejdning af pozzolaner
DK1844662T3 (da) Metode til belægning af objekter
DK3106873T3 (da) Fremgangsmåde til detektering af cancer
BRPI0911077A2 (pt) método para tratamento de biomassa
DK2452189T3 (da) Fremgangsmåde til identifikation af forbindelser til behandling af cancer
DK2498731T3 (da) Fremgangsmåder til behandling eller forebyggelse af stenttrombose
BRPI0815550A2 (pt) Método para estabilizar fenilefrina
DK3214083T3 (da) Fremgangsmåde til fremstilling af quinolonforbindelser
DK2358661T3 (da) Fremgangsmåde til fremstilling af trans-4-amino-cyclohexyl-eddikesyreethylester-hcl
DK2382232T3 (da) Fremgangsmåde til fremstilling af bivalirudin
DK2554171T3 (da) Fremgangsmåde til behandling af sygdomme
DK2441462T3 (da) Fremgangsmåde til behandling af type I-diabetes
DK2262739T5 (da) Fremgangsmåde til neutralisering af mikroorganismer